In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Stephanie A NestorowDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
Wan-Na ChenDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
Caroline E WyattDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
Martin MortensenDepartment of Neuroscience, Physiology and Pharmacology, University College London, London, UK.ORCID 0000-0002-5873-7107 Thomas ClairfeuilleRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Basel, Switzerland.
Michael ReutlingerRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Basel, Switzerland.ORCID 0000-0001-9393-108X Gregoire FrizRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland.
Giuseppe CecereRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Basel, Switzerland.ORCID 0000-0001-5004-8932 Trevor G SmartDepartment of Neuroscience, Physiology and Pharmacology, University College London, London, UK.ORCID 0000-0002-9089-5375 Maria-Clemencia HernandezRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland.ORCID 0000-0003-1621-4188 Lisa JoedickeRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, Basel, Switzerland. lisa.joedicke@roche.com.
Funding
Medical Research Council MR/T002581/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/M024709/1
6 · The paper itselfAbstract
γ-aminobutyric acid Type-A (GABA
Indexed as
Receptors, GABA-AAllosteric RegulationAnimalsBinding SitesCryoelectron Microscopygamma-Aminobutyric AcidHumansModels, MolecularProtein Subunitsgamma-Aminobutyric AcidProtein SubunitsReceptors, GABA-A
Identifiers
PMID42749722
PMCPMC13582853
What OpenQuestion holds
Textmetadata
Read underepoch 390